Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (30)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hill, M. E.
Right arrow Articles by Hammans, S. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hill, M. E.
Right arrow Articles by Hammans, S. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol. 124, No. 3, 522-526, March 2001
© 2001 Oxford University Press

Oculopharyngeal muscular dystrophy

Phenotypic and genotypic studies in a UK population

M. E. Hill1, G. A. Creed2, T. F. W. McMullan2, A. G. Tyers3, D. Hilton-Jones4, D. O. Robinson2 and S. R. Hammans1

1 Wessex Neurology Centre, Southampton General Hospital, 2 Wessex Regional Genetics Laboratory and 3 Department of Ophthalmology, Salisbury District Hospital and 4 Radcliffe Infirmary, Oxford, UK

Correspondence to: Simon Hammans, Wessex Neurological Centre, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK

Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant disorder of late onset that commonly presents with ptosis and dysphagia. The genetic basis of the condition has been identified recently as a stable trinucleotide repeat expansion in exon 1 of the poly(A) binding protein 2 gene (PABP2), in which (GCG)6 is the normal repeat length. The prevalence of OPMD is greatest in patients of French-Canadian origin. It is not clear if expansion repeat length is a reliable test in other populations. In this study, we analysed the phenotypic and genotypic characteristics of 31 patients with OPMD in the UK. Ptosis was the first reported symptom in two-thirds of the patients, and half of the subjects studied had evidence of ophthalmoplegia. All but one family had a pathological expansion in the PABP2 gene, ranging from (GCG)8 to (GCG)13. In contrast to the French-Canadian population, (GCG)10 was almost as common as (GCG)9, evidence against a strong founder effect in the UK population. There was a weak association between repeat length and age of disease onset. Patients with longer repeat lengths, such as (GCG)13, developed severe limb weakness early in the disease. We were unable to detect the (GCG)7 polymorphism in over 200 normal controls, suggesting that the frequency of this expansion is lower than that found in the French-Canadian population. One family was negative for the expansion. Affected members presented with the classical features of OPMD, namely ptosis, dysphagia and cytoplasmic inclusions on muscle biopsy, although with some atypical features, such as early age of onset, high serum levels of creatine kinase and a profound ophthalmoplegia. This family is an example of a GCG expansion-negative oculopharyngeal syndrome requiring further genetic investigation. We conclude that PABP2 analysis is a reliable non-invasive diagnostic test for OPMD in the UK population.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Br J OphthalmolHome page
D Rivera, H Mejia-Lopez, E N Pompa-Mera, C Villanueva-Mendoza, A Nava-Castaneda, L Garnica-Hayashi, S Cuevas-Covarrubias, and J C Zenteno
Two different PABPN1 expanded alleles in a Mexican population with oculopharyngeal muscular dystrophy arising from independent founder effects
Br J Ophthalmol, July 1, 2008; 92(7): 998 - 1002.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
T Jenkins, S Al-Sarraj, and M Rose
Oculopharyngeal myopathy with inflammation and calcinosis: an unusual phenotype
J. Neurol. Neurosurg. Psychiatry, June 1, 2008; 79(6): 731 - 733.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
D O Robinson, A J Wills, S R Hammans, S P Read, and J Sillibourne
Oculopharyngeal muscular dystrophy: a point mutation which mimics the effect of the PABPN1 gene triplet repeat expansion mutation.
J. Med. Genet., May 1, 2006; 43(5): e23 - e23.
[Abstract] [Full Text] [PDF]

Home page
 ptjournalHome page
R. M Lovering, N. C Porter, and R. J Bloch
The Muscular Dystrophies: From Genes to Therapies
Physical Therapy, December 1, 2005; 85(12): 1372 - 1388.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
J. Amiel, D. Trochet, M. Clement-Ziza, A. Munnich, and S. Lyonnet
Polyalanine expansions in human
Hum. Mol. Genet., October 1, 2004; 13(suppl_2): R235 - R243.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
D. L. Dedrick and L. K. Brown
Obstructive Sleep Apnea Syndrome Complicating Oculopharyngeal Muscular Dystrophy
Chest, January 1, 2004; 125(1): 334 - 336.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
M. W. Becher, L. Morrison, L. E. Davis, W. C. Maki, M. K. King, J. M. Bicknell, B. L. Reinert, C. Bartolo, and D. G. Bear
Oculopharyngeal Muscular Dystrophy in Hispanic New Mexicans
JAMA, November 21, 2001; 286(19): 2437 - 2440.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.